All Cancer articles – Page 19
-
ArticleUsing AI to predict metastatic behaviour of NSCLC
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
-
NewsCombatting T-cell tumours with antibody drug conjugates
One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models.
-
NewsReversing malignant cancer cells to a normal state
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
-
News
MUTYH variants implicated in a broader range of cancers
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
-
ArticleBreaking resistance – the future of immunotherapy in oncology
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
-
NewsThe first core regulatory circuit identified for ALCL
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
-
NewsNew strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
-
NewsThe mechanism of PARP inhibitor action is identified
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
-
NewsExact bacterial lineage associated with colorectal cancer pinpointed
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
-
NewsPotential for personalised, molecularly guided UTUC treatments
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
-
Article
The advancement of drug-free immunotherapy
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
-
Article
Optimised antibody panels for CTC and rare cell enumeration
Despite significant strides in cancer research, metastasis remains the primary cause of cancer-related mortality globally. Joby Chesnick and Tracey Long, from the Digital Biology Group and Life Science Group, respectively, at BioRad Laboratories, reveal how investigation into circulating tumour cells (CTCs) and other rare cell types has led to the ...
-
NewsNew link between FBXW7 mutations and EGFR signalling identified
The Organoid Group have discovered a link between FBXW7 mutations and the EGFR signalling pathway, which could improve colorectal cancer treatments.
-
NewsTargeting cancer cells in early hypoxia
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.
-
NewsTargeting Inc-HLX-2-7 shrinks group 3 medulloblastoma tumours
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.
-
NewsP47 suppresses metastasis of HER2-positive breast cancer
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
-
News
How fusion proteins drive paediatric cancer
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.
-
NewsNew algorithm identifies high-risk precancerous lesions
Researchers have developed an algorithm which could improve diagnostics of ovarian high-grade serous carcinoma.
-
ArticleBreakthrough for pancreatic cancer treatment
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
-
ArticleScalable precision design targeting complex product profiles
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.